Floatz logo

1H-ISOINDOL-1-ONE, 7-((6-((DIMETHYLAMINO)METHYL)-5-((3S)-TETRAHYDRO-3-FURANYL)-2-PYRIDINYL)AMINO)-4-(7-FLUOROIMIDAZO(1,2-A)PYRIDIN-3-YL)-2,3-DIHYDRO-

Non-Small Cell Lung Cancer

Nimbus Saturn, Inc.Small moleculePhase 1/2Active
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
59/ 100

Competitive context

1205 Active assets in the Non-Small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Zoledronate
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4BBB
Onartuzumab
Hoffmann-La Roche
Phase 3BBB

View all 50 →

Same molecule, other indications

1H-ISOINDOL-1-ONE, 7-((6-((DIMETHYLAMINO)METHYL)-5-((3S)-TETRAHYDRO-3-FURANYL)-2-PYRIDINYL)AMINO)-4-(7-FLUOROIMIDAZO(1,2-A)PYRIDIN-3-YL)-2,3-DIHYDRO- is also rated in:

renal cell carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
gastroesophageal adenocarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
neoplasmDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →